Emergent BioSolutions appoints Sujata Dayal to board; compliance expert joins committees

Emergent BioSolutions Inc.

Sujata Dayal appointed Class II director effective July 15, 2022; term expires at 2023 annual meeting.
Also appointed to Nominating and Corporate Governance Committee and Special Committee on Manufacturing and Quality Oversight.
Dayal is VP and Global Chief Compliance Officer at Medline Industries; previously VP healthcare compliance at Johnson & Johnson.
She will receive an initial equity award of $375,000 in RSUs vesting one-third per year for three years.
Dayal is an attorney with expertise in healthcare compliance, regulatory law, and anti-corruption.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sujata Dayal

Class II Director

EBS · Emergent BioSolutions Inc.

Effective: 2022-07-15
Filed: July 6, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Sujata Dayal as a Class II director of the Company, effective as of July 15, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sujata Dayal was appointed as Class II Director at Emergent BioSolutions Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Sujata Dayal as a Class II director of the Company, effective as of July 15, 2022

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-22-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.